Parisi Gray Wealth Management Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Parisi Gray Wealth Management raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 12.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,360 shares of the company's stock after buying an additional 689 shares during the quarter. Eli Lilly and Company comprises 1.7% of Parisi Gray Wealth Management's portfolio, making the stock its 17th largest holding. Parisi Gray Wealth Management's holdings in Eli Lilly and Company were worth $5,253,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Knightsbridge Asset Management LLC increased its position in shares of Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the last quarter. Centerpoint Advisory Group bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $514,000. LS Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after acquiring an additional 40 shares during the last quarter. Kentucky Trust Co purchased a new position in Eli Lilly and Company in the fourth quarter worth $834,000. Finally, CSM Advisors LLC increased its stake in Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after acquiring an additional 245 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 4.4%

Shares of LLY traded up $34.04 on Tuesday, reaching $807.75. The stock had a trading volume of 4,738,640 shares, compared to its average volume of 3,653,811. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The firm has a market capitalization of $765.54 billion, a price-to-earnings ratio of 68.98, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The company has a 50-day simple moving average of $769.95 and a 200-day simple moving average of $800.81.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.58 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. Eli Lilly and Company's payout ratio is presently 48.82%.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on LLY shares. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.